Advertisement


Lisa A. Carey, MD, and Richard S. Finn, MD, on Breast Cancer: Findings From the PALOMA-1/TRIO 18 Trial

2017 ASCO Annual Meeting

Advertisement

Lisa A. Carey, MD, of the University of North Carolina, and Richard S. Finn, MD, of UCLA Medical Center, discuss phase II overall survival findings on palbociclib in combination with letrozole vs letrozole alone for front-line treatment of ER+/HER2– advanced breast cancer. (Abstract 1001)



Related Videos

Issues in Oncology

Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates

Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatment of metastatic solid tumors. (Abstract LBA2)

Rakesh Chopra, MD, on Global Health Care: Expert Perspective

Rakesh Chopra, MD, of India’s Artemis Hospitals, discusses ASCO’s Role in global cancer care and the issues he finds most pressing.

Colorectal Cancer

Temidayo Fadelu, MD, on Colon Cancer: Results From the CALGB 89803 Trial

Temidayo Fadelu, MD, of Dana-Farber Cancer Institute, discusses study findings on nut consumption and survival in stage III colon cancer patients. Higher consumption of nuts may be associated with significantly reduced cancer recurrence and death in this group. (Abstract 3517)

Head and Neck Cancer
Issues in Oncology

Maura L. Gillison, MD, PhD, on HPV and the Value of the Vaccine

Maura L. Gillison, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the impact of prophylactic human papillomavirus vaccination on oral HPV infections among young adults in the United States. (Abstract 6003)

Lung Cancer
Colorectal Cancer

David H. Henry, MD, on Advances in Lung Cancer, Colorectal Cancer: Expert Perspective

David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.

Advertisement

Advertisement




Advertisement